AMENDMENT NO. 2 to EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 14th, 2015 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 (this “Amendment No. 2”), dated as of June 15, 2015, is entered into between Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute, a Washington non-profit corporation (“Licensor”) and Juno Therapeutics, Inc., a Delaware corporation (“Licensee”).
AMENDMENT #2 TO LICENSE AGREEMENT ST. JUDE File No.: SF-03-0018License Agreement • August 14th, 2015 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
AMENDED AND RESTATED MASTER RESEARCH AND COLLABORATION AGREEMENT by and among JUNO THERAPEUTICS, INC. and CELGENE CORPORATION and CELGENE RIVOT LTD. Dated as of August 13, 2015License Agreement • August 14th, 2015 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED MASTER RESEARCH AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of August 13, 2015 (the “Execution Date”) by and among Juno Therapeutics, Inc., a Delaware corporation (“Juno”), and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations under this Agreement in the United States, and Celgene RIVOT Ltd. (“Celgene RIVOT”), with respect to all rights and obligations under this Agreement outside the United States (Celgene RIVOT and Celgene Corp., together, “Celgene”). Celgene and Juno are each referred to herein by name or as a “Party”, or, collectively, as the “Parties.”
AMENDMENT AND WAIVER OF FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF JUNO THERAPEUTICS, INC. July 27, 2015Investors’ Rights Agreement • August 14th, 2015 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment and Waiver dated as of July 27, 2015 (the “Amendment and Waiver”) amends and waives certain provisions of that certain Fourth Amended and Restated Investors’ Rights Agreement dated as of December 5, 2014 (the “Agreement”), between Juno Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors named therein. Capitalized terms used herein without definition shall have the meanings given in the Agreement.
FIRST AMENDMENT TO LEASELease • August 14th, 2015 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 31st day of July, 2015, by and between BMR-217th PLACE LLC, a Delaware limited liability company (“Landlord”), and JUNO THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
NON-EXCLUSIVE SUBLICENSE AGREEMENTNon-Exclusive Sublicense Agreement • August 14th, 2015 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • August 14th, 2015 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “First Amendment”) is made as of May 21, 2015, by and between ARE-SEATTLE NO. 16, LLC, a Delaware limited liability company (“Landlord”), and JUNO THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
